Apheresis Platelets Reduce De Novo HLA Antibody Formation After Heart Transplantation: Real World Data from a Retrospective Multicenter Study
This retrospective multicenter study of 223 heart transplant recipients demonstrates that intraoperative transfusion of apheresis platelets, compared to pooled platelet concentrates, is associated with a significantly lower risk of developing de novo HLA antibodies within one year, suggesting that preferential use of apheresis platelets may reduce alloimmunization and improve long-term outcomes.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
When a heart fails and cannot be repaired, the only path forward is often a transplant. But the human immune system, designed to protect the body from invaders, sees a new heart as a foreign threat. To prevent the body from attacking this new organ, doctors must carefully manage the patient's immune response. A major hurdle in this process is the development of antibodies against human leukocyte antigens, or HLA. These are proteins found on the surface of almost every cell in the body. If a patient's immune system learns to recognize the donor's HLA proteins as enemies, it can launch a silent, damaging attack on the new heart, leading to rejection or long-term failure.
This sensitization often happens before the transplant even occurs. It can be triggered by pregnancy, previous surgeries, or blood transfusions. Among blood products, platelets—tiny cell fragments essential for clotting—pose a unique risk. Unlike red blood cells, platelets are covered in a high density of these HLA proteins. When a patient receives a transfusion of platelets, they are essentially being exposed to a large amount of foreign immune material. For decades, hospitals have used two main types of platelet preparations. One type, called pooled platelets, is made by mixing platelets from four to six different donors into a single bag. The other type, apheresis platelets, comes from a single donor, meaning the patient is exposed to the immune material of only one person. The question of which type is safer for heart transplant candidates has been a subject of debate, balancing the higher cost and complexity of single-donor products against the theoretical risk of sensitization from multiple donors.
Researchers from three major German university hospitals set out to examine this question using real-world data from over a decade of heart transplants. They looked back at the records of 223 adult patients who received heart transplants between 2011 and 2021. The team wanted to see if the type of platelet transfusion a patient received during or shortly after surgery influenced whether they developed new HLA antibodies in the year following the operation. They also took a close look at the broader picture of how these hospitals were currently using blood products, noting that many centers had already shifted toward single-donor platelets to minimize donor exposure.
The study revealed a striking difference in outcomes based on the type of platelet transfusion. Among the small group of ten patients who received only pooled platelets—those mixed from multiple donors—seven developed new HLA antibodies within a year. That is a rate of 70 percent. In contrast, among the 167 patients who received only apheresis platelets from a single donor, 46 developed new antibodies, a rate of 28 percent. While the number of patients in the pooled group was small, the trend was clear: those exposed to multiple donors were far more likely to become sensitized. The researchers noted that even among patients who received no platelet transfusions at all, about a quarter still developed new antibodies, highlighting that sensitization is a complex process influenced by many factors, including other blood products and the surgery itself.
The analysis also considered other known risk factors. Patients who had been supported by a durable mechanical pump, known as a ventricular assist device, before their transplant were significantly more likely to have antibodies already present before the surgery. Similarly, women who had been pregnant previously showed a higher likelihood of pre-existing antibodies, as the immune system can react to the father's genetic material passed to the fetus. However, when the researchers focused specifically on the platelet transfusions, the data suggested that the single-donor apheresis platelets were associated with a lower risk of triggering new antibody formation compared to the pooled versions.
Despite these findings, the researchers were careful to frame their conclusions with appropriate caution. The group of patients who received pooled platelets was very small, which limits the statistical certainty of the results. When they tried to build a complex mathematical model to account for all the different variables—such as age, gender, the number of transfusions, and prior surgeries—the clear link between pooled platelets and antibody formation became less distinct. This suggests that while the single-donor platelets appear safer, other factors in a patient's medical history also play a major role. The study did not prove that pooled platelets definitely cause rejection, but it strongly suggests they carry a higher risk of sensitization.
The findings align with a growing shift in clinical practice. Many transplant centers have already moved toward using single-donor apheresis platelets as a standard precaution, driven by the desire to minimize the number of different donors a patient is exposed to. This study provides real-world evidence supporting that shift, showing that in a high-risk group like heart transplant recipients, the choice of blood product matters. While the cost and logistical effort of single-donor platelets are higher, the data suggests that the potential benefit of reducing the risk of immune sensitization could be significant for the long-term health of the new heart. The researchers concluded that while larger, prospective studies are needed to confirm these results with absolute certainty, the current evidence points toward favoring single-donor platelets to help protect transplant recipients from the complications of a sensitized immune system.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.